Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells

Cell Death and Disease

Volumn 5, Issue 5, 2014, Pages

  Boridy, S ^a   Le, P U ^b   Petrecca, K ^b   Maysinger, D ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

17 AAG; Autophagy; Celastrol; Glioblastoma; Heat shock protein 90; P62 SQSTM1

Indexed keywords

6 N ACETYLCYSTEINYLDIHYDROCELASTROL; ACETYLCYSTEINE; CASPASE 3; CELASTROL; CYCLOHEXIMIDE; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P62; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL DESTRUCTION; CELL DEATH; CELL SURVIVAL; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; FEEDBACK SYSTEM; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN QUALITY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BENZOQUINONES; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLIOBLASTOMA; HOMEOSTASIS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LYSOSOMES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS; TRITERPENES; TUMOR CELLS, CULTURED; UBIQUITINATION;

EID: 84901012573     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.182     Document Type: Article

References (68)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
3. Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca AC et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta 2012; 1826: 338-349.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
5. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 2013; 331: 139-146.
6. Easaw JC, Mason WP, Perry J, Laperriere N, Eisenstat DD, Del Maestro R et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 2011; 18: e126-e136.
7. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013; 15: 930-935.
8. Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 2011; 17: 301-312.
9. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 2012; 5: 631-643.
10. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 2011; 16: 1028-1041.
11. Lee JH,Won YS, Park KH, LeeMK, Tachibana H, Yamada K et al. Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis 2012; 17: 1275-1286.
12. Tozawa K, Sagawa M, Kfki M. Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-kappaB pathway. Int J Oncol 2011; 39: 1117-1122.
13. Jung HW, Chung YS, Kim YS, Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 2007; 39: 715-721.
14. Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 2010; 303: 9-20.
15. Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, Park JH et al. Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Invest 2009; 39: 819-827.
16. Paimela T, Hyttinen JM, Viiri J, Ryhanen T, Karjalainen RO, Salminen A et al. Celastrol regulates innate immunity response via NF-kappaB and Hsp70 in human retinal pigment epithelial cells. Pharmacol Res 2011; 64: 501-508.
17. Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y et al. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat Nanotechnol 2010; 5: 354-359.
18. Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE et al. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db Mice. PLoS One 2013; 8: e62068.
19. Ge P, Ji X, Ding Y, Wang X, Fu S, Meng F et al. Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurol Res 2010; 32: 94-100.
20. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008; 264: 101-106.
21. Chen M, Rose AE, Doudican N, Osman I, Orlow SJ. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res 2009; 7: 1946-1953.
22. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 2010; 285: 11498-11507.
23. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W et al. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett 2010; 297: 155-164.
24. Kim Y, Kang H, Jang SW, Ko J. Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem 2011; 28: 175-184.
25. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006; 72: 1311-1321.
26. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNFinduced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaBregulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007; 109: 2727-2735.
27. Shao L, Zhou Z, Cai Y, Castro P, Dakhov O, Shi P et al. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS One 2013; 8: e58391.
28. Chen G, Zhang X, Zhao M, Wang Y, Cheng X, Wang D et al. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer 2011; 11: 170.
29. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968; 74: 465-486.
30. Westermark B, Ponten J, Hugosson R. Determinants for the establishment of permanent tissue culture lines from human gliomas. Acta Pathol Microbiol Scand A 1973; 81: 791-805.
31. Ponten J, Westermark B. Properties of human malignant glioma cells in vitro. Med Biol 1978; 56: 184-193.
32. Khatchadourian A, Krumova K, Boridy S, Ngo AT, Maysinger D, Cosa G. Molecular imaging of lipid peroxyl radicals in living cells with a BODIPY-alpha-tocopherol adduct. Biochemistry 2009; 48: 5658-5668.
33. Seo WY, Goh AR, Ju SM, Song HY, Kwon DJ, Jun JG et al. Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells. Biochem Biophys Res Commun 2011; 407: 535-540.
34. Klaic L, Trippier PC, Mishra RK, Morimoto RI, Silverman RB. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol. J Am Chem Soc 2011; 133: 19634-19637.
35. Castello PR, Drechsel DA, Patel M. Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem 2007; 282: 14186-14193.
36. Walcott SE, Heikkila JJ. Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells. Comp Biochem Physiol A Mol Integr Physiol 2010; 156: 285-293.
37. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine,' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758-4765.
38. Deng YN, Shi J, Liu J, Qu QM. Celastrol protects human neuroblastoma SH-SY5Y cells from rotenone-induced injury through induction of autophagy. Neurochem Int 2013; 63: 1-9.
39. Wang WB, Feng LX, Yue QX, Wu WY, Guan SH, Jiang BH et al. Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J Cell Physiol 2012; 227: 2196-2206.
40. Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 2012; 19: 1337-1346.
41. Conn CS, Qian SB. Nutrient signaling in protein homeostasis: An increase in quantity at the expense of quality. Sci Signal 2013; 6: ra24.
42. Chow AM, Brown IR. Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones 2007 Autumn 12: 237-244.
43. Wang Y, Gibney PA, West JD, Morano KA. The yeast Hsp70 Ssa1 is a sensor for activation of the heat shock response by thiol-reactive compounds. Mol Biol Cell 2012; 23: 3290-3298.
44. Arora S, Yang JM, Hait WN. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 2005; 65: 3806-3810.
45. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
46. Ding QH, Cheng Y, Chen WP, Zhong HM, Wang XH. Celastrol, an inhibitor of heat shock protein 90beta potently suppresses the expression of matrix metalloproteinases, inducible nitric oxide synthase and cyclooxygenase-2 in primary human osteoarthritic chondrocytes. Eur J Pharmacol 2013; 708: 1-7.
47. Sreeramulu S, Gande SL, Gobel M, Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl 2009; 48: 5853-5855.
48. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 2009; 284: 35381-35389.
49. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997; 272: 23843-23850.
50. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995; 38: 3813-3820.
51. Cruickshanks N, Shervington L, Patel R, Munje C, Thakkar D, Shervington A. Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma? Cancer Invest 2010; 28: 608-614.
52. Jane EP, Pollack IF. The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett 2008; 268: 46-55.
53. Seo HR, Seo WD, Pyun BJ, Lee BW, Jin YB, Park KH et al. Radiosensitization by celastrol is mediated by modification of antioxidant thiol molecules. Chem Biol Interact 2011; 193: 34-42.
54. Zhang Y, Ahn YH, Benjamin IJ, Honda T, Hicks RJ, Calabrese V et al. HSF1-dependent upregulation of Hsp70 by sulfhydryl-reactive inducers of the KEAP1/NRF2/ARE pathway. Chem Biol 2011; 18: 1355-1361.
55. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004; 10: 549-557.
56. Miyata Y, Rauch JN, Jinwal UK, Thompson AD, Srinivasan S, Dickey CA et al. Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70. Chem Biol 2012; 19: 1391-1399.
57. Zhu H, Yang W, He LJ, Ding WJ, Zheng L, Liao SD et al. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLoS One 2012; 7: e52333.
58. Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene 2009; 28: 2556-2568.
59. Singha PK, Pandeswara S, Venkatachalam MA, Saikumar P. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis 2013; 4: e457.
60. Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ 2013; 20: 21-30.
61. Komatsu M, Kageyama S, Ichimura Y. p62/SQSTM1/A170: physiology and pathology. Pharmacol Res 2012; 66: 457-462.
62. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137: 1062-1075.
63. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137: 1001-1004.
64. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282: 24131-24145.
65. Su H, Wang X. p62 Stages an interplay between the ubiquitin-proteasome system and autophagy in the heart of defense against proteotoxic stress. Trends Cardiovasc Med 2011; 21: 224-228.
66. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 2009; 33: 517-527.
67. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10: 221-237.
68. Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 2009; 27: 1722-1733.